2014-03-12 03:32:02 -
Quintiles last night was named the “Best CRO in Asia” at the 2014 BioPharma Asia Industry Awards dinner, the third time in the event’s four-year history that Quintiles has received the honor. The award recognizes the contract research organization that has best demonstrated an ongoing commitment to improve clinical research in Asia and help customers succeed.
“This award reflects Quintiles’ ability to improve our customers’ probability of success by combining market knowledge with superior service,” said Ken Lee, M.D., Quintiles Vice President and Regional General Manager for Southeast Asia, who accepted the award. “For 20 years we’ve been helping our customers navigate Asia’s complex and changing healthcare environment. It’s wonderful to be acknowledged for our excellence in bringing knowledge and people
together for a healthier world.”
In the last two years, Quintiles has continued to expand its integrated services in Asia-Pacific, including.
- Launching a late phase research offering, Real World and Late Phase Research, to help companies, governments and payers determine the value of new medicines in real-world use.
- Significantly expanding its local CRO in China, Kun Tuo, which complements its global offering through Quintiles China.
- Adding anatomic pathology, genomics and flow cytometry testing capabilities to its central laboratories in Singapore, Beijing, Tokyo and Mumbai, India.
The awards dinner was part of the 7 th Annual BioPharma Asia Convention in Singapore, where yesterday Karen Wai, M.D., MBA, Quintiles’ Head of Site Services Asia, made a presentation titled “Innovative Site Strategies” about data-driven site selection in Asia.
Anand Tharmaratnam, M.D., Quintiles Senior Vice President and Head of Asia-Pacific, said of the award, “I’d like to dedicate to this to our employees, whose excellence made it possible; to our valued customers; and to patients worldwide whose lives and quality of life depend on new and better medicines.”
Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 28,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top 50 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww ..
Click here : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fale ..
to subscribe to Mobile Alerts for Quintiles.
" title="http://cts.businesswire.com/ct/CT?id=bwnews&sty=20140311006723r1&sid=16929&distro=ftp\"/>" target="_blank" rel="nofollow">cts.businesswire.com/ct/CT?id=bwnews&sty=20140311006723r1&am ..
QuintilesMedia Relations:Jay Johnson, +65.6602.1297 (office)Mobile:
: mailto:firstname.lastname@example.org orInvestor
Relations:Karl Deonanan, +1-919-998-2789 InvestorRelations@quintiles.com